Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Moodys
Express Scripts
Harvard Business School
McKesson

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Litigation Details for MERCK SHARP & DOHME CORP. v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2009)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

MERCK SHARP & DOHME CORP. v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2009)

Docket   Start Trial Date Filed 2009-12-16
Court District Court, D. New Jersey Date Terminated 2012-04-27
Cause 35:271 Patent Infringement Assigned To Jose L. Linares
Jury Demand Defendant Referred To Magistrate Judge Michael A. Ha
Parties MERCK SHARP & DOHME CORP.; MSD INTERNATIONAL GMBH; MSP SINGAPORE COMPANY LLC; MYLAN INC.; MYLAN PHARMACEUTICALS INC.; PHV JAMES SUH; SCHERING CORPORATION; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.
Patents 5,273,995; 5,767,115; 5,846,966; RE37,721; RE42,461
Attorneys ALLYN ZISSEL LITE; ARNOLD B. CALMANN; CRISTINA BARAGONA; CRISTINA FINETTI; DONALD A. ROBINSON; DOUGLAS SCOTT EAKELEY; JAKOB BENJAMIN HALPERN; JASON E. HALPER; JEFFREY S. SOOS; MAYRA VELEZ TARANTINO; MICHAEL E. PATUNAS; RITA DARLENE TURNER
Firms Hdlogix, Inc.; Lowenstein Sandler; Lowenstein Sandler PC; Patunas Law LLC; Patunas Tarantino LLC
Link to Docket External link to docket
Small Molecule Drugs cited in MERCK SHARP & DOHME CORP. v. MYLAN PHARMACEUTICALS INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for MERCK SHARP & DOHME CORP. v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2009)

Date Filed Document No. Description Snippet Link To Document
2011-05-17 195 Schering’s patents, specifically United States Patent Nos. RE37,721 (“the ‘721 patent”) and 5,846,966 (“the…issuance of the ‘721 patent. (SOF ¶ 3.) Specifically, an initial patent, United States Patent No. 5,757,115…the ‘966 patent”) (collectively, the “patents-in-suit”). (Schering’s Local …that the patents-in-suit are unenforceable for inequitable conduct by Schering during patent term extension…during the pendency of the patent term extension application for the ‘721 patent, Schering violated the External link to document
2011-06-15 209 thereof.” Pfizer, 457 F.3d at 1291; see U.S. Patent No. 5,273,995. The Federal Circuit did not flatly hold… This patent infringement case involves two patents, the ‘721 patent and the ‘966 patent. The ‘721…United States Patent No. RE37,721 (“the ‘721 patent”) and claims 1 and 3 of United States Patent No. 5,846,966…issued the original patent in 1998 as U.S. Patent No. 5,757,115 (“the ‘115 patent”) and thereafter reissued…the ‘721 patent and claims 1 and 3 of the ‘966 patent.3 Claims 8 and 12 of the ‘721 patent read as follows External link to document
2011-06-15 210 language of United States Patent No. RE37,721 and United States Patent No. 5,846,966, etc., Signed by Judge…2009 27 April 2012 2:09-cv-06383 830 Patent Defendant District Court, D. External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Harvard Business School
Medtronic
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.